Nuvalent, Inc.
8-K
June 9, 2026
Key Highlights
- GSK to acquire Nuvalent for $124.00 per share in cash
- Nuvalent to become a wholly-owned subsidiary of GSK
- Fixed acquisition price eliminates volatility from drug trial news
Read Analysis
🤖 AI Generated